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Aims
The quick diagnosis of Burkitt's lymphoma (BL) and its
clear-cut differentiation from diffuse large B-cell lym-
phoma (DLBCL) is of great clinical importance since treat-
ment for these two disease entities differ markedly and
should promptly be initiated in BL. However, these two
tumours are difficult to distinguish using the current
WHO classification, particularly in regard to BL variants,
i.e., BL with plasmacytoid differentiation and atypical
Burkitt's/Burkitt's-like lymphomas.
Methods
We studied 39 cases of highly proliferative blastic B-cell
lymphoma (HPBCL) to establish a practical differential-
diagnostic algorithm. Characteristics set for BL were a typ-
ical morphology, a mature B-cell phenotype of CD10+,
Bcl-6+ and Bcl-2- tumour cells, a proliferation rate of
>95%, and the presence of C-MYC rearrangements in the
absence of t(14;18)(q32;q21). All cases were selectively
negative for cyclin D-1, CD5, CD23, LMP-EBV, CD34 and
TdT, and there were no cases of endemic or immunodefi-
ciency-associated Burkitt's lymphoma.
Results
Altogether the set BL characteristics were found in only 5/
39 cases (12.8%), whereas the majority of tumours
revealed mosaic features (87.2%). In a second attempt, we
followed a pragmatic stepwise approach for a classifica-
tion algorithm that includes the assessment of C-MYC sta-
tus to stratify HPBCL into four predefined diagnostic
categories (DC), namely DC I (5/39, 12.8%): "classical
BL", corresponding to the classical variant of sporadic BL
in the WHO classification; DC II (11/39, 28.2%): "atypi-
cal BL", corresponding to the atypical Burkitt's/Burkitt's-
like variants of sporadic BL in the WHO classification; DC
III (9/39, 23.1%): "C-MYC+ DLBCL"; and DC IV (14/39,
35.9%): "C-MYC- HPBCL".
Conclusion
This proposal may serve as a robust and objective opera-
tional basis for therapeutic decisions for HPBCL within
one week and is applicable to be evaluated for its prognos-
tic relevance in prospective clinical trials.
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